Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022

SELL
$2.25 - $9.99 $36,900 - $163,836
-16,400 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$15.91 - $21.88 $60,458 - $83,144
3,800 Added 30.16%
16,400 $263,000
Q2 2021

Aug 03, 2021

BUY
$20.49 - $35.63 $84,009 - $146,083
4,100 Added 48.24%
12,600 $338,000
Q1 2021

Apr 29, 2021

BUY
$18.99 - $33.2 $161,415 - $282,200
8,500 New
8,500 $271,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $199M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.